Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Syndecan binding protein 2 (SDCBP2), also known as syntenin-2, is a protein encoded by the SDCBP2 gene and contains two class II PDZ domains. These domains allow SDCBP2 to facilitate protein-protein interactions, particularly by binding to the cytoplasmic C-terminus of transmembrane proteins. SDCBP2 is involved in cell signaling, organization of protein complexes, and regulation of nuclear phosphatidylinositol 4,5-bisphosphate (PIP2), contributing to cell division and survival. It is a scaffolding protein important for intracellular signaling complex formation. While implicated in rare disorders such as hyperekplexia and studied in the context of cell growth and survival, there are no approved drugs directly targeting SDCBP2, and its role in disease is not fully characterized
Not applicable (no reported drugs targeting SDCBP2)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Syndecan binding protein 2 (SDCBP2).